Alluvi, formerly LY3414901, represents a exciting advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable effectiveness in early clinical data, with impressive weight lo